Q BioMed Inc. (QBIO)

Market Cap	843.82K
Revenue (ttm)	284,352
Net Income (ttm)	-3.53M
Shares Out	70.32M
EPS (ttm)	-0.14
PE Ratio	n/a
Forward PE	109.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,007
Open	0.0100
Previous Close	0.0120
Day's Range	0.0100 - 0.0120
52-Week Range	0.0050 - 0.2200
Beta	2.22
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About QBIO

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership wi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 3
• Stock Exchange: OTCMKTS
• Ticker Symbol: QBIO

Financial Performance

In 2022, Q BioMed's revenue was $284,352, an increase of 45.38% compared to the previous year's $195,597. Losses were -$716,095, -91.66% less than in 2021.